Novel Antibacterial Agents

Award Information
Agency:
Department of Defense
Amount:
$69,891.00
Program:
STTR
Contract:
N00014-09-M-0357
Solitcitation Year:
2009
Solicitation Number:
2009.A
Branch:
Navy
Award Year:
2009
Phase:
Phase I
Agency Tracking Number:
N09A-033-0128
Solicitation Topic Code:
N09-T033
Small Business Information
PolyMedix, Inc.
170 N. Radnor-Chester Road, Suite 300, Radnor, PA, 19087
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
621470033
Principal Investigator
 Richard Scott
 VP Research, PolyMedix
 (484) 598-2336
 rscott@polymedix.com
Business Contact
 Dawn Eringis
Title: Director Scientific Affairs, PolyMe
Phone: (484) 598-2334
Email: deringis@polymedix.com
Research Institution
 University of Massachusetts, Amhers
 Carol P Sprague
 Research Administration Bldg
70 Butterfield Terrace
Amherst, MA, 1003
 (413) 545-0698
 Nonprofit college or university
Abstract
The need for novel antibiotics is well understood by anyone familiar to the field. We have discovered a novel class of antibiotics that are structurally unique from all previously known antibiotics and appear to operate via a distinctive mode of action. As a result, these new agents appear to represent significant promise as new treatments for the emerging problem of MDR infections. In less than 5 years, PolyMedix has translated one of these novel molecules from discovery to Phase 1a human clinical trials with a planned indication to broadly treat Staphylococcal infections including methicillin-resistant S. aureus. This proposal describes our efforts to develop lead compounds against those pathogens most relevant to military personnel with a specific focus on Acinetobacter and P. aeruginosa.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government